ERBB2 and neoplasm: Through molecular pathological studies, we have obtained new tumor diagnostic markers, such as HER-2, EGFR and KRAS. Furthermore, many therapeutic drugs specific to various cancers, such as trastuzumab, gefitinib and rituximab, have also been identified [21,22].